MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma

European Journal of Cancer

Volumn 47, Issue 1, 2011, Pages 151-161

  Robinson, Cleo ^a   Walsh, Amy ^a   Larma, Irma ^a   O'Halloran, Sean ^b   Nowak, Anna K ^a   Lake, Richard A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Animal models of cancer; Asbestos induced mesothelioma; Cancer prevention; Chemotherapy; Prognostic factors

Indexed keywords

ASBESTOS; CELECOXIB; GEMCITABINE; PROTEIN TAG; THIOGLYCOLIC ACID;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; PATHOGENESIS; PERITONITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; TRANSGENE; TRANSGENIC MOUSE; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASBESTOS; CONTACTIN 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; IRRITANTS; MALE; MESOTHELIOMA; MICE; MICE, TRANSGENIC; PERITONEAL NEOPLASMS; THIOGLYCOLATES;

EID: 78650415162     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.08.015     Document Type: Article

References (45)

1. M. Albin, C. Magnani, S. Krstev, E. Rapiti, and I. Shefer Asbestos and cancer: an overview of current trends in Europe Environ Health Perspect 107 Suppl 2 1999 289 298
2. M. Nurminen, A. Karjalainen, and K. Takahashi Estimating the induction period of pleural mesothelioma from aggregate data on asbestos consumption J Occup Environ Med 45 10 2003 1107 1115
3. B.P. Lanphear, and C.R. Buncher Latent period for malignant mesothelioma of occupational origin J Occup Med 34 7 1992 718 721
4. H.L. Kindler Systemic treatments for mesothelioma: standard and novel Curr Treat Options Oncol 9 2-3 2008 171 179
5. J. Cuzick, J. Forbes, and R. Edwards First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 9336 2002 817 824
6. A.B. Kane Animal models of malignant mesothelioma Inhal Toxicol 18 12 2006 1001 1004
7. C. Robinson, I. van Bruggen, and A. Segal A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent Cancer Res 66 22 2006 10786 10794
8. D. Urwin, and R.A. Lake Structure of the mesothelin/MPF gene and characterization of its promoter Mol Cell Biol Res Commun 3 1 2000 26 32
9. P.A. Moalli, J.L. MacDonald, L.A. Goodglick, and A.B. Kane Acute injury and regeneration of the mesothelium in response to asbestos fibers Am J Pathol 128 3 1987 426 445
10. A. Reid, G. Berry, and N. de Klerk Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite) Chest 131 2 2007 376 382
11. A. Reid, G. Berry, J. Heyworth, N.H. de Klerk, and A.W. Musk Predicted mortality from malignant mesothelioma among women exposed to blue asbestos at Wittenoom, Western Australia Occup Environ Med 66 3 2009 169 174
12. S. Metintas, M. Metintas, I. Ucgun, and U. Oner Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area Chest 122 6 2002 2224 2229
13. E. Pira, C. Pelucchi, and L. Buffoni Cancer mortality in a cohort of asbestos textile workers Brit J Cancer 92 3 2005 580 586
14. P. Cocco, and M. Dosemeci Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix Am J Ind Med 35 1 1999 9 14
15. D.D. Smith Women and mesothelioma Chest 122 6 2002 1885 1886
16. A.K. Nowak, B.W. Robinson, and R.A. Lake Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 15 2003 4490 4496
17. M. Yao, S. Kargman, and E.C. Lam Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice Cancer Res 63 3 2003 586 592
18. S. Gupta, V.M. Adhami, and M. Subbarayan Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model Cancer Res 64 9 2004 3334 3343
19. J.G. Edwards, S.P. Faux, and S.M. Plummer Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 8 6 2002 1857 1862
20. J. Fleury-Feith, C. Lecomte, and A. Renier Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours Oncogene 22 24 2003 3799 3805
21. D.A. Altomare, C.A. Vaslet, and K.L. Skele A mouse model recapitulating molecular features of human mesothelioma Cancer Res 65 18 2005 8090 8095
22. C.A. Vaslet, N.J. Messier, and A.B. Kane Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice Toxicol Sci 68 2 2002 331 338
23. G. Klein, A. Powers, and C. Croce Association of SV40 with human tumors Oncogene 21 8 2002 1141 1149
24. F. Lopez-Rios, P.B. Illei, V. Rusch, and M. Ladanyi Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids Lancet 364 9440 2004 1157 1166
25. A. Ziegler, C.A. Seemayer, and M. Hinterberger Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results Lung Cancer 57 3 2007 282 291
26. H.D. Strickler, J.J. Goedert, and S.S. Devesa Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines J Natl Cancer Inst 95 1 2003 38 45
27. A. Procopio, L. Strizzi, and G. Vianale Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma Genes Chromosomes Cancer 29 2 2000 173 179
28. R.S. Du Toit An estimate of the rate at which crocidolite asbestos fibres are cleared from the lung Ann Occup Hyg 35 4 1991 433 438
29. G. Berry, and J.C. Wagner Effect of age at inoculation of asbestos on occurrence of mesotheliomas in rats Int J Cancer 17 4 1976 477 483
30. J.P. Steele, A. Klabatsa, and D.A. Fennell Prognostic factors in mesothelioma Lung Cancer 49 Suppl 1 2005 S49 S52
31. A.W. Musk, and N.H. de Klerk Epidemiology of malignant mesothelioma in Australia Lung Cancer 45 Suppl 1 2004 S21 S23
32. M.L. Newhouse, G. Berry, J.C. Wagner, and M.E. Turok A study of the mortality of female asbestos workers Brit J Ind Med 29 2 1972 134 141
33. D.S. Heller, R.E. Gordon, P.B. Clement, R. Turnnir, and N. Katz Presence of asbestos in peritoneal malignant mesotheliomas in women Int J Gynecol Cancer 9 6 1999 452 455
34. N. Kurumatani, and S. Kumagai Mapping the risk of mesothelioma due to neighborhood asbestos exposure Am J Respir Crit Care Med 178 6 2008 624 629
35. M.M. Maule, C. Magnani, and P. Dalmasso Modeling mesothelioma risk associated with environmental asbestos exposure Environ Health Perspect 115 7 2007 1066 1071
36. J.A. Han, J.I. Kim, and P.P. Ongusaha P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis Embo J 21 21 2002 5635 5644
37. S.H. Ali, and J.A. DeCaprio Cellular transformation by SV40 large T antigen: interaction with host proteins Semin Cancer Biol 11 1 2001 15 23
38. S.L. O'Kane, L. Cawkwell, A. Campbell, and M.J. Lind Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma Eur J Cancer 41 11 2005 1645 1648
39. B.W. Robinson, and R.A. Lake Advances in malignant mesothelioma New Engl J Med 353 15 2005 1591 1603
40. A.K. Nowak, B.W. Robinson, and R.A. Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 8 2002 2353 2358
41. A.K. Nowak, M.J. Byrne, and R. Williamson A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma Brit J Cancer 87 5 2002 491 496
42. M.J. Byrne, J.A. Davidson, and A.W. Musk Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study J Clin Oncol 17 1 1999 25 30
43. N.J. Vogelzang, C. Porta, and L. Mutti New agents in the management of advanced mesothelioma Semin Oncol 32 3 2005 336 350
44. J.P. van Meerbeeck, R. Gaafar, and C. Manegold Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 28 2005 6881 6889
45. M.E. O'Brien, D. Watkins, and C. Ryan A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial Ann Oncol 17 2 2006 270 275